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Abstract 
The failure of a majority of clinical trials in progressive MS has 
highlighted the need to reconsider how these trials are designed and 
conducted, and many areas deserve focus. Basic scientists are 
reconceptualising the pathophysiology of progressive MS into three broad 
areas: systemic inflammation, compartmentalized inflammation and non-
inflammatory neurodegeneration, with the latter two becoming predominant 
as the disease progresses. This reconceptualization will guide the choice of 
experimental therapies. Previous clinical trials have highlighted how 
participant selection can have a significant impact on study outcome. Phase 2 
biomarkers which are biologically stable, dynamically changing over time, and 
easy to assess in multi-centre studies are greatly needed. Shortcomings 
inherent in the Expanded Disability Status Scale is prompting the development 
and validation of better clinical measures. The standard 2-arm, fixed-duration 
trial paradigm has been challenged with new, innovative approaches that can 
test more therapies efficiently. International collaboratives such as the 
Progressive MS Alliance will support increased dialog with regulators, industry, 
and other funding agencies. Better engagement with people living with 
progressive MS will transform them from simply being the object of MS 
therapies to partners in the search for therapies. Focused, targeted action will 
drive further development of effective therapies for progressive MS. 
 
 
  
Multiple sclerosis (MS) typically starts as a relapsing remitting disease of 
the central nervous system, with repeated waves of inflammatory damage and 
neurologic dysfunction and is called relapse remitting MS (RRMS). After a 
decade or more, MS frequently transforms into a gradually progressive 
condition, with insidious worsening of neurologic function and is called 
secondary progressive MS (SPMS). In a minority of patients, the relapsing 
phase is skipped and the disease is gradually progressive from the very 
beginning and is called primary progressive MS (PPMS). Despite different 
antecedents, PPMS and SPMS appear to be more similar than they are 
different, so are often grouped together and called progressive MS. 
Whilst the growing number of disease modifying therapies (DMT) in 
relapsing-remitting multiple sclerosis (RRMS) has been eagerly received,1 the 
treatment landscape for progressive multiple sclerosis has remained 
stubbornly limited.2 The few treatments for progressive MS is not from lack of 
effort. There have been dozens of clinical trials, and extensive effort has been 
expended to better understand the disease and potential treatment 
approaches. Despite these efforts, the treatment landscape is quite limited. 
This review examines different aspects of clinical trials for progressive MS. 
Further discussion of each of these topics is contained in the nine companion 
papers in this issue of Multiple Sclerosis Journal.  
 People Living with Progressive MS 
Traditionally, people living with MS (PwMS) had little role in MS clinical 
trials except to volunteer their bodies as testing grounds for new therapies. 
More recently, however, PwMS have assumed greater roles in the search for 
treatments for their disease. Some of this shift comes from governmental fiat, 
such as where health authorities, grant organizations, and regulators require 
patient representation in the clinical trial process. The SPRINT-MS trial 
included a PwMS as a member of the Protocol Steering Committee, as required 
by the National Institutes of Health.3 The DISCO study of MS therapy 
discontinuation has involved PwMS throughout the study’s development and 
implementation, as required by its US federal funder, Patient-Centered 
Outcomes Research Institute. Foundations have integrated PwMS into their 
leadership structure, too, such as the Scientific Steering Committee of the 
Progressive MS Alliance (www.progressivemsalliance.org). 
This shift has brought a recognition that PwMS are not simply the object 
of MS therapies, but can (and should) play important roles in the research 
process. They share personal expertise and knowledge about the disease, 
which can impact study protocols by incorporating participant needs and 
views. Their insights into the experience of living with MS can help focus the 
development and choice of outcome metrics towards clinically meaningful 
measures. PwMS can be advocates for MS research by promoting financial 
support for research from funding agencies. PwMS can advocate throughout 
the MS community and elsewhere to raise awareness about the obstacles, 
limitations, and opportunities related to MS research. They can also improve 
study recruitment and retention, both through improvements in study designs 
that ease study participation and helping to educate the MS community 
regarding the importance of clinical trial enrolment and long-term 
participation. 
This increased partnership comes with obligations. Clinical trials have 
traditionally had poor communication back to participants regarding trial 
results. This silence disenfranchises participants from the research process and 
dehumanizes their contributions. Those who organize clinical trials need to 
better plan how they share study results back to those who volunteered their 
bodies for the betterment of MS. PwMS also expect that their trial data is 
made available outside of the immediate trial investigators so that the data 
may better inform future research. Despite these expectations, clinical trial 
data sharing is still in its infancy.  
In summary, the MS clinical trial enterprise is learning to better partner 
with PwMS to improve and accelerate the clinical trial process. This 
partnership will benefit both PwMS and the research enterprise.  
 
Lessons Learnt from Progressive MS Trials  
The disappointment that derived from several decades of progressive 
MS trials with negative outcomes has been buoyed lately by several positive 
progressive MS clinical trials. Simvastatin,4 biotin,5 ocrelizumab,6 and 
siponimod7 have all demonstrated positive outcomes in phase 2 or 3 trials, and 
these results have pointed towards potential treatment avenues. This 
excitement is tempered by the anti-inflammatory effects of some of these 
therapies and sub-group analyses that suggest that the predominant benefit is 
derived from the subset of participants with active inflammation before the 
trial. 
The positive and negative trials provide insight into important aspects of 
the trial population. Revised phenotype criteria published in 2014 now allow 
for relapsing and progressive MS to occur simultaneously, thus recognizing the 
overlapping aspects of the inflammation that underlies relapsing MS and the 
other, yet-to-be-defined pathophysiology of progressive MS. Age, disease 
severity, co-morbidities and rapidity of progression are all now recognized to 
be important potential factors impacting study outcome and response to 
treatment. Enrolling subjects who are likely to have progression over the 
course of the trial is important, since those who don’t progress will not 
contribute to measuring a therapy designed to slow progression. Several 
efforts are underway to better identify these subjects. 
 
Pathology 
The disappointing outcome of so many therapies in progressive MS trials 
has prompted basic scientists to reconsider the previously held notions 
regarding the pathophysiology of progressive MS.8 A cardinal presumption has 
been that relapsing and progressive MS have the same underlying 
pathophysiology, but that appears unlikely. Instead, there are a myriad of 
potential pathologies, including B and T lymphocyte dysregulation, primary 
demyelination and neurodegeneration. This state of affairs is dynamic, and 
likely shifts over the course of the disease, which is highly relevant for timing of 
target intervention. Potential links in the chain of injury in progressive MS 
include microglial activation, reactive oxygen/nitric oxide, cellular injury, 
mitochondrial damage, ionic imbalance, compounded by vascular 
hypoperfusion and iron accumulation. The end-pathology can be tri-
categorised: systemic inflammation, compartmentalized inflammation and 
non-inflammatory neurodegeneration. As MS evolves into progressive MS, the 
role of systemic inflammation appears to wane and either compartmentalized 
inflammation or neurodegeneration (or both) become predominant. Novel 
approaches are required, particularly for compartmentalized inflammation and 
neurodegeneration. 
The failure of oligodendrocyte precursors to differentiate and 
remyelinate naked axons in MS remains a mystery and provides an adjunctive 
treatment approach for progressive MS. The reasons for the failure of 
remyelination is not known but may involve loss of endogenous progenitor 
cells, the blockade of differentiation into myelinating cells, and a generally 
hostile tissue environment. The disappointing effect of a monoclonal antibody 
specifically developed to target remyelination highlights the challenge for 
remyelinating therapies.9 
 
Participant Selection  
When designing a clinical trial a fundamental parameter is the type of 
patient that is entered into the process, which is of course a human 
experiment. If inclusion criteria are too wide, it may lead to an amplification of 
natural variability, which may drown out any nascent signal of therapeutic 
benefit. On the other hand, if entry criteria are too stringent, then external 
validity and generalizability become compromised.   
The PROMISE trial of glatiramer acetate in PPMS found increased rates 
of progression for males and those with either CSF oligoclonal bands or 
gadolinium enhancement (GdE) at baseline.10 The OLYMPUS trial of rituximab 
in PPMS found that younger patients and those with GdE at baseline were 
more likely to benefit from therapy.11 These findings directly guided the 
inclusion criteria for the ORATORIO study of ocrelizumab, where subject age 
was capped at 55 years and disease duration at 10-15 (depending upon 
disability level). Similar to OLYMPUS, the ORATORIO study found a greater 
clinical benefit in the 25% of subject with GdE at baseline.6 By limited age and 
disease duration, the generalizability of the ORATORIO study to the broader 
PPMS patient population, with older age and longer disease duration, is 
unknown.  
Detailed analysis study of the population characteristics from 
progressive MS trials is instructive in guiding eligibility requirements for the 
next tranche of trials. Sub-group analyses provides insight into both subject 
characteristics that predict future disability as well as characteristics that are 
more likely to respond to therapeutic intervention. 
 
Clinical Measures 
Measuring progression in clinical trials has been challenging, and the 
optimal outcome measure is not well established.12 The traditional Expanded 
Disability Status Scale (EDSS) is limited in its scoring vagaries and sensitivity to 
change over time. Electronic scoring of the Neurostatus EDSS has become 
available which has reduced rater scoring error. Alternative clinical measures 
have arisen from the MS Functional Composite, including time 25-foot walk, 9-
hole peg test, low contrast letter acuity, paced auditory serial addition test 
(PASAT), and the symbol digit modality test (SDMT). These newer measures 
have demonstrated subject validity, appropriate scale behaviour and relevance 
of change over time, although each measures only a small portion of 
neurologic function affected by MS. Cut-points for meaningful changes in these 
metrics have been developed and will continue to be validated and refined by 
subsequent studies. 
Composite outcomes combine metrics together to define progression 
and have been used with good success in trials such as the INFORMS trial of 
fingolimod,13 where over 70% of subjects demonstrated sustained progression 
on the composite over 3 years. The optimal mixture of measures and operative 
logic (i.e. combining measures using “or” vs “and”) is not yet established. 
Increased sensitivity using composites need to be further validated, including 
how the measures are weighted. 
 Cognition is highlighted as a particular area of interest. The replacement 
of PASAT by SDMT in clinical trials appears secure, although SDMT is an 
incomplete cognitive test. The optimal composition of cognitive testing 
batteries is unknown and needs to balance completion time (and thus subject 
and investigator burden) with sensitivity. Cognition is a very common symptom 
reported by PwMS and therefore deserves a prominent place in future clinical 
trials. 
 Patient Reported Outcomes (PROs) remain an important component of 
clinical trials, since they provide grounding to patient’s experience of the 
disease. There continues a tension between MS-specific (e.g., MSIS-29) and 
MS-non-specific (e.g., EQ5D) measurements. In relapsing MS trials, PROs have 
often not demonstrated benefit of therapy, despite positive outcomes on 
relapses and sustained progression of disability. As a result, PROs remain an 
adjunctive outcome, and whether they can become primary outcomes in 
disease-modifying treatments in progressive MS remains an unanswered 
question. 
 In summary, EDSS has yet to be toppled from a regulatory and scientific 
standpoint. However, increasingly concerted approaches using a variety of 
substantial datasets continue to evolve the clinical measurement of 
progressive MS. Their outcome promises a richer and more dynamic clinical 
measurement stick in the future. 
 
Phase 2 Trial Biomarkers 
The development of therapies for progressive MS can be accelerated by 
effective Phase 2 trial outcomes. Phase 2 trials are intended to provide proof-
of-concept evidence of efficacy through short trials, involving a small number 
of subjects, using a biomarker as the primary outcome. In relapsing MS, phase 
2 trials are typically six months in duration and involve 50-75 subjects per 
treatment arm. A similar structure is desired for progressive MS. Where new 
T2 or gadolinium enhancing lesions are the most common biomarker outcome 
for phase 2 trials in relapsing MS, the equivalent biomarker in progressive MS 
is unknown. Fluid, electrophysiology, and imaging biomarkers provide 
attractive candidate biomarkers. 
Fluid Biomarkers. Neurofilament light (NfL) is a major protein contained 
in axons and is frequently shed into the cerebrospinal fluid when nervous 
tissue is damaged. Any damage can lead to increased NfL in CSF, which in MS 
includes neuroinflammation and neurodegeneration. NfL crosses readily into 
the blood stream, and recent studies have demonstrated blood NfL to be a 
good estimate of NfL in the CSF.14 NfL has been shown to be a good measure of 
treatment response in RRMS and also correlates with disability progressive in 
progressive MS. Ongoing studies will define normative values, biologic 
variability, and optimal testing methods. Several ongoing clinical trials will 
evaluate the potential use of NfL as a biomarker in progressive MS trials. 
Additional potential fluid biomarkers include matrix metalloproteinase-
9, chemokine ligand 13, chitinase-3-like-1, and osteopontin. The biologic 
variability, testing stability, standardization for testing, and clinical relevance is 
less known for these biomarkers, which make them further from potential 
employment in a progressive MS trial. 
Electrophysiology Biomarkers. Evoked potentials are quantitative 
measures of neurologic function and could be useful as biomarkers in 
progressive MS trials. Multi-focal visual evoked potentials were used as the 
primary outcome in the RENEW study of a remyelinating therapy of acute optic 
neuritis,9 although has not yet been used in progressive MS. Like other 
biomarkers, the biologic variability, reproducibility, dynamic change over time, 
and multi-centre standardization is still being developed. 
Imaging Biomarkers. Whole brain atrophy has been the most accepted 
and utilized imaging outcome for phase 2 trials of progressive MS.15 Limitations 
include biologic variability, its slow change over time, and it being only a single 
value per subject, which limits granularity of assessment. Regional atrophy (i.e. 
grey matter volume and thalamic volume) have received some attention, since 
they appear to be more responsive to RRMS treatments. Optimal 
measurement techniques remain unknown. Spinal cord atrophy may provide a 
more specific measure of injury relevant in progressive MS. Challenges with 
spinal cord atrophy include its very small size, motion from CSF flow, and its 
presence on only the most caudal brain image slices, where artefacts are more 
likely. Although some have advocated for registration-based methods over 
segmentation-based for atrophy measures, the evidence supporting one 
atrophy method over another is too limited at present. 
Advanced imaging methods such as magnetization transfer ratio, 
diffusion tensor imaging, and optical coherence tomography have the potential 
to provide more pathologically specific measures of tissue integrity with 
greater dynamic range and change over time. The voxel-level characterization 
available with advanced MRI measures may provide a tissue-level granularity 
that makes them more powerful metrics than either whole-brain or regional 
atrophy measures. Challenges with advanced imaging methods include a 
limited understanding of their biologic variability and dynamic change over 
time, the challenges in multi-centre implementation, and little experience 
using them in multi-centre trials.  
A challenge for all advanced imaging measures is the potential impact of 
changes in technology over time. MRI scanners frequently receive upgrades, 
and the impact of changes in pulse sequence, coils, and other hardware is 
mostly unknown and difficult to predict. Currently, clinical trial analyses 
exclude intervals across a scanner change, which significantly reduces the 
statistical power of trials. Several ongoing trials using these measures will 
provide important insight into their potential use as biomarkers in progressive 
MS, as well as methods to overcome some of the technical challenges. 
 
Clinical Trial Design 
A significant threat to finding effective therapies in progressive MS is 
flawed trial designs. Several important aspects of trial design have become 
recognized recently. 
The population enrolled in the trial is important. The presence of 
inflammatory activity at baseline is important with anti-inflammatory 
therapies, since subjects without inflammatory activity are less likely to 
respond to anti-inflammatory therapies. Age, sex, duration of disease, 
disability levels, and rate of progression can each have an impact on the 
resultant disease course and response to therapy.  
The choice of phase 2 outcome is key to any trial’s design, and the lack 
of consensus regarding a reliable, sensitive, dynamic biomarker for progressive 
MS is a challenge. Brain atrophy is the current standard, but therapeutic lag 
and pseudo-atrophy from anti-inflammatory effects of some therapies can 
confound measures of brain atrophy. Delaying baseline can help reduce this 
confounding, but decreases study power by shortening the interval of outcome 
measurement.  
Clinical outcomes in phase 3 trials also pose a challenge for trial designs. 
EDSS has poor reliability and statistical characteristics, and composites have 
met with resistance from regulatory agencies. Quality of Life metrics have a 
similarly difficult statistical performance which make them very difficult to 
power using feasible sample sizes.  
Finally, the traditional placebo vs active trials using frequentist statistical 
modelling has been challenged lately. Adaptive trials, where treatment choices 
are dynamically influenced by the contemporary study experience, allow for 
more therapies to be evaluated simultaneously, with the better therapies 
emerging over the course of the study. Adaptive trials can be based upon 
Bayesian statistical methods, which can provide flexibility in the design and 
analysis of study results.  
 
Regulatory and Funding Aspects 
 
Progressive MS trials are not conducted in isolation, but rather within a 
regulatory environment and using significant financial support. Phase 3 
outcomes require regulatory acceptance for market approval. In 2015, the 
European Medicines Agency issued guidelines that encouraged the 
development of alternative scales to assess disability, but acknowledged that 
at that time, EDSS was the only validated outcome measurement to determine 
disability.16 A common misperception that biomarkers need regulatory 
approval to be used in progressive MS phase 2 trials. Most progressive MS 
phase 3 trials had no phase 2 trials demonstrating efficacy, which highlights 
how regulators don’t require any evidence of efficacy from phase 2 trials. 
Similarly, T2 and gadolinium-enhancing lesions are typical primary outcomes 
for most RRMS phase 2 trials, yet they have never received formal regulatory 
approval for this purpose. The regulatory focus in phase 2 trials is on safety; 
proof-of-concept efficacy (i.e. using a biomarker) generally is not a regulatory 
concern in phase 2 trials. 
 Phase 2 and 3 clinical trials in progressive MS costs between tens and 
hundreds of millions of US dollars to conduct. Commercial support for 
progressive MS trials has been fuelled by the commercial success of approved 
relapsing MS therapies and the promise of similar success in progressive MS. 
This euphoria has waned after so many studies failed to meet their primary 
outcomes. A return to basics is needed to reinvigorate the process. This 
includes a better understanding of the true pathophysiology of progressive 
MS; benchtop models of progressive MS to test potential treatment targets 
and ligands; useful phase 2 biomarkers; sensitive clinical measures of disability 
progression and its improvement from therapies intended to restore function. 
Increased support for progressive MS trials will results from improvements in 
the process of developing and testing the therapies. 
 The vital need to gather together academic, commercial, and patient 
advocacy organizations is realized with the Progressive MS Alliance and its 
Industry Forum. The Alliance has already provided a useful forum for dialog 
with federal regulators. To promote a continuous and meaningful dialogue is at 
the heart of the endeavour, and key priority areas of research have been 
identified.  
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